l-Nucleoside enantiomers as antivirals drugs: A mini-review

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 276-281

  Mathé, Christophe ^a   Gosselin, Gilles ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

Antiviral drugs; l Nucleoside enantiomers

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ABACAVIR; ACICLOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; CLEVUDINE; DIDANOSINE; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; FORMIVIRSEN; FOSCARNET; GANCICLOVIR; IDOXURIDINE; LAMIVUDINE; LEVOVIRIN; NUCLEOSIDE DERIVATIVE; RIBAVIRIN; STAVUDINE; TELBIVUDINE; TENOFOVIR DISOPROXIL; TRIFLURIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALGANCICLOVIR; VALTORCITABINE; VIDARABINE; ZALCITABINE; ZIDOVUDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; ENANTIOMER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; PRIORITY JOURNAL; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; HEPATITIS B VIRUS; HUMANS; NUCLEOSIDES; STEREOISOMERISM; VIRUS DISEASES; VIRUSES;

HEPATITIS B VIRUS;

EID: 33747158845     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.04.017     Document Type: Short Survey

References (41)

1. Asif G., Hurwitz S.J., Gumina G., Chu C.K., McClure H.M., and Schinazi R.F. Pharmacokinetics of the antiviral agent β-l-3′-fluoro-2′,3′-didehydro-2′,3′-d ideoxycytidine in rhesus monkeys. Antimicrob. Agents Chemother. 49 (2005) 560-564
2. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith III A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., and Kozalska G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94: a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46 (2002) 2365-2372
3. Cameron J.M., Collins P., Daniel M., and Storer R. Lamivudine. Drugs Fut. 18 (1993) 319-323
4. Chen H., Pai S.B., Hurwitz S.J., Chu C.K., Glazkova Y., McClure H.M., Feitelson M., and Schinazi R.F. Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-β-l-glyceropent-2-enofuranosyl)cytosine. Antimicrob. Agents Chemother. 47 (2003) 1922-1928
5. Chen S.-H. Comparative evaluation of l-Fd4C and related nucleoside analogs as promising antiviral agents. Cur. Med. Chem. 9 (2002) 899-912
6. Cheng Y.-C. l-nucleoside analogues against cancer-causing viruses have potential in the prevention, delayed onset and treatment of viral associated cancers. Antiviral Chem. Chemother. 12 Suppl. 1 (2001) 5-11
7. Chu C.K., Ma T.W., Shanmuganathan K., Wang C.-G., Xiang Y.-J., Pai S.B., Yao G.-Q., Sommadossi J.-P., and Cheng Y.-C. Use of 2′-fluoro-5-methyl-β-l-arabinofuranosyl uracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. 39 (1995) 979-981
8. De Clercq E. Antiviral drug discovery and development: where chemistry meets biomedicine. Antiviral Res. 67 (2005) 56-75
9. De Clercq E. Recent highlights in the development of new antiviral drugs. Curr. Opin. Microbiol. 8 (2005) 552-560
10. Focher F., Spadari S., and Maga G. Antivirals at the mirror: the lack of stereospecificity of some viral and human enzymes offers novel opportunities in antiviral drug development. Curr. Drug Targets Infect. Disord. 3 (2003) 41-53
11. Furman P.A., and Painter G.R. The role of absolute configuration in the anti-HIV and anti-HBV activity of nucleoside analogues. Int. Antiviral News 3 (1995) 74-77
12. Gero A.M., Dunn C.G., Brown D.M., Pulenthiran K., Gorovits E.L., Bakos T., and Weis A.L. New malaria chemotherapy developed by utilization of a unique parasite transport system. Curr. Pharm. Design 9 (2003) 867-877
13. Gershburg E., and Pagano J.S. Epstein-Barr virus infection: prospects for treatment. J. Antimicrob. Chemother. 56 (2005) 277-281
14. Gosselin G., Pierra C., Benzaria S., Dukhan D., Imbach J.-L., Loi A.G., La Colla P., Cretton-Scott E., Bridges E.G., Standring D., and Sommadossi J.-P. β-l-2′-deoxythymidine (ldT) and β-l-2′-deoxycytidine (ldC): How simple structures can be potent, selective and specific anti-HBV drugs. In: Schinazi R.F., and Liotta D.C. (Eds). Frontiers in Nucleosides and Nucleic Acids (2004), IHL Press 309-317
15. Gourdeau H., Leblond L., Hamelin B., Dong K., Ouellet F., Boudreau C., Custeau D., Richard A., Gilbert M.-J., and Jolivet J. Species differences in troxacitabine pharmacokinetics and pharmacodynamics. Clin. Cancer Res. 10 (2004) 7692-7702
16. Graciet J.-C., and Schinazi R.F. From d- to l-nucleoside analogs as antiviral agents. Adv. Antiviral Drug Des. 3 (1999) 1-68
17. Grattan M.T., Moreno-Cabral C.E., Starnes V.A., Stinson E.B., and Shumway N.E. Cytomegalovirus infection is associated with cardiac allograph rejection and atherosclerosis. JAMA 261 (1989) 3561-3566
18. Gumina G., Song G.-Y., and Chu C.K. l-nucleosides as chemotherapeutic agents. FEMS Microbiol. Lett. 202 (2001) 9-15
19. Gumina G., Chong Y., Choo H., Song G.-Y., and Chu C.K. l-nucleosides: antiviral activity and molecular mechanism. Curr. Top. Med. Chem. 2 (2002) 1065-1086
20. Huang Y., Ostrowitzki S., Hill G., Navarao M., Berger N., Kopeck P., Cheng I.M., Alfredson T., and Lal R. Single and multiple-dose pharmacokinetics of levovirin valinate hydrochloride (R1518) in healthy volunteers. J. Clin. Pharmacol. 45 (2005) 578-588
21. Jarvis B., and Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58 (1999) 101-141
22. Kim J.W., Park S.H., and Louie S.G. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann. Pharmacother. 40 (2006) 472-478
23. Lai C.-L., Leung N., Teo E.-K., Tong M., Wong F., Hann H.-W., Han S., Poynard T., Myers M., Chao G., Lloyd D., and Brown N.A. A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
24. Lalezari J.P., Aberg J.A., Wang L.H., Wire M.B., Miner R., Snowden W., Talarico C.L., Shaw S., Jacobson M.A., and Drew W.L. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 42 (2002) 2969-2976
25. Lu H., and Thomas S. Maribavir (ViroPharma). Curr. Opin. Invest. Drugs 5 (2004) 898-906
26. Mansour T.S., and Storer R. Antiviral nucleosides. Curr. Pharm. Design 3 (1997) 227-264
27. Marcellin P., Mommeja-Marin H., Sacks S.L., Lau G.K.K., Sereni D., Bronowicki J.-P., Conway B., Trepo C., Blum M.R., Yoo B.C., Mondou E., Sorbel J., Snow A., Rousseau F., and Lee H.-S. A phase dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40 (2004) 140-148
28. Maury G. The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: A new strategy?. Chemother. Antiviral Chem. 11 (2000) 165-190
29. McKenzie R., Travis M.W.D., Dolan S.A., Pitaluga I.M., Feuerstein I.M., Shelhamer J., Yoarchoan R., and Masur H. The cause of death in patients with human immunodeficiency virus infection: a clinical and pathological study with emphasis on the role of pulmonary disease. Medicine 70 (1991) 326-343
30. Nair V., and Jahnke T.S. Antiviral activities of isomeric dideoxynucleosides of d- and l-related stereochemistry. Antimicrob. Agents Chemother. 39 (1995) 1017-1029
31. Nelson, M., 2003. Telbivudine (l-dT) in phase III studies for chronic hepatitis B. HEP DART, December 14-18, Kauai, Hawai.
32. Pai S.B., Pai R.B., Xie M.-Y., Beker T., Shi J., Tharnish P.M., Chu C.K., and Schinazi R.F. Characterization of hepatitis B virus inhibition by novel 2′-fluoro-2′,3′-unsaturated beta-d- and l-nucleosides. Antiviral Chem. Chemother. 16 (2005) 183-192
33. Saag M.S. Emtricitabine, a new antiretroviral agent with activity against HIV and Hepatitis B virus. Clin. Infect. Dis. 42 (2006) 126-131
34. Sia I.G., and Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev. 13 (2000) 83-121
35. Smejkal J., and Sorm F. Nucleic acid components and their analogues. 53. Preparation of 1-(2-deoxy-β-l-ribofuranosyl)thymidine (l-thymidine). Collect. Czech. Chem. Commun. 29 (1964) 2809-2813
36. Walker M.P., Appleby T.C., Zhong W., Lau J.Y.N., and Hong Z. Hepatitis C virus therapies: current treatments, targets and future perspectives. Antiviral Chem. Chemother. 14 (2003) 1-21
37. Wang P., Hong J.H., Cooperwood J.S., and Chu C.K. Recent advances in l-nucleosides: chemistry and biology. Antiviral Res. 40 (1998) 19-44
38. Wingard J.R., Piantadosi W.H., Burns W.H., Zahurak M.L., Santos G.W., and Saral R. Cytomegalovirus infections in bone marrow transplant recipients given cytoreductive therapy. Rev. Infect. Dis. 12 Suppl. 7 (1990) S793-S804
39. Yoo B.C., Chung Y.-H., Han B.H., Byun K.S., Lee H.-J., Chon C.Y., Kim Y.S., Cho S.-H., Park J.-W., Lee Y.-J., Yang J.-M., Lee M.-S., Yang J.-M., Lee M.-S., Yoo K., Jeong S.-H., Kim D.-G., Yoo H.-W., Otto M.J., Furman P.A., and Lee H.-S. Clevudine is highly efficacious in HBeAg(-) chronic hepatitis B patients with a sustained antiviral effect after cessation of therapy. Hepatology 42 Suppl. 1 (2005) 268A
40. Yoo B.C., Kim J.H., Lee K.S., Kim T.-H., Paik S.W., Ryu S.H., Han J.-Y., Cho M., Hwang S.G., Kim B.-I., Lee Y.-S., Kim H.C., Hwang J.S., Choi S.-K., Kim Y.S., Kweon Y.-O., Choi J.-Y., Lee H.Y., Yoo H.-W., Otto M.J., Furman P.A., and Lee H.-S. A 24-week clevudine monotherapy produced profound on-treatment viral suppression as well as sustained viral suppression and normalization of aminotransferase levels for 24 weeks off-treatment in HBeAg(+) chronic hepatitis B patients. Hepatology 42 Suppl. 1 (2005) 270A
41. Zemlicka J. Enantioselectivity of the antiviral effects of nucleoside analogues. Pharmacol. Ther. 85 (2000) 251-266